Dyadic International, Inc.

NASDAQ:DYAI

Biotechnology

Healthcare
$1.47 +21.49%

+$0.26 today

Market cap
$53.56M
Beta
1.15
P/E (TTM)
-6.9
EPS (TTM)
-$0.20
52W Low $0.65High $1.55

Volume 0.71M

Average 0.31M

DYAI Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Dyadic International, Inc.NASDAQ: DYAI

Revenue · Q1 FY2026 · quarter ended Mar 2026

Revenue growth accelerates

Q1 FY2026 revenue of $1.11M rose 506.7% year over year, ahead of the -11.0% change in trailing-twelve-month revenue. Sequentially, it rose 371.3% from the prior quarter. Over 3 fiscal years it compounded at -25.1% a year.

Context

  • Revenue increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether revenue reaches the consensus estimate from 2 analysts of $6.82M (+453.3%) for the fiscal year ending Dec 2026, a step up from the -64.7% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.11M+371.3% QoQ
Last fiscal yearDec 2025
$1.23M-64.7% YoY
LTMMar 2026
$2.97M-11.0% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+506.7%+121.3%-385.5 pp
1 year-64.7%+453.3%+518.1 pp
3-year CAGR-25.1%+107.4%+132.5 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
1.23M USD
Year-over-year change
-64.7%
4-year CAGR
-15.4%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How DYAI compares with its peers on the latest reported figures

  • Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
  • Its year-over-year change of -11.0% is the 3rd highest of 5, against a peer median of -7.9%.
  • Over three fiscal years its annual growth of -25.1% compares with a peer median of +7.9%.
DYAI Competitors
Revenue for DYAI and competitors
Company Period LTM YoY 3-year CAGR
CELUCelularity Inc.LTM Dec 2025$26.55M USD-51.0%+13.9%
ATHEAlterity Therapeutics LimitedFY2025A$5.44M AUD+35.3%+2.0%
DYAIDyadic International, Inc.LTM Mar 2026$2.97M USD-11.0%-25.1%
RNXTRenovoRx, Inc.LTM Mar 2026$1.49M USD+520.4%—
MAIAMAIA Biotechnology, Inc.LTM Mar 2026$0 USD——
PYPDPolyPid Ltd.LTM Mar 2026$0 USD——
VERUVeru Inc.LTM Mar 2026$0 USD-100.0%—
ANVSAnnovis Bio, Inc.LTM Mar 2026$0 USD——
Peer median (excluding DYAI) —-7.9%+7.9%

Competitors are the stored peer set for DYAI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.4M2.93M2.9M3.5M1.23M
Cost of Revenue1.94M2.12M1.98M1.19M2.32M
Gross Profit459.39K807.11K922.96K2.3M(1.09M)
Gross Margin19.1%27.5%31.8%65.8%-88.3%
Research & Development8.39M4.5M3.3M2.04M2.15M
Selling, General & Admin6.7M6.42M5.82M6.13M5.76M
Operating Expenses15.19M10.97M9.15M8.2M6.06M
Depreciation & Amortization3.49M038.42K00
EBITDA(11.14M)(10.12M)(8.15M)(5.38M)(6.91M)
EBITDA Margin-463.4%-345.2%-281.3%-154.0%-560.6%
Operating Income(14.73M)(10.17M)(8.23M)(5.9M)(7.15M)
Operating Margin-612.7%-346.9%-283.9%-168.8%-579.9%
Interest Income51.7K180.42K416.69K456.99K284.09K
Interest Expense000427.97K455.9K
Other Income / Expenses1.66M430.42K1.43M91.66K(218.71K)
Income Before Tax(13.07M)(9.74M)(6.8M)(5.81M)(7.36M)
Pre-Tax Margin-543.7%-332.2%-234.4%-166.2%-597.6%
Income Tax Expense00000
Net Income(13.07M)(9.74M)(6.8M)(5.81M)(7.36M)
Net Margin-543.7%-332.2%-234.4%-166.2%-597.6%
EPS (Basic)(0.47)(0.34)(0.24)(0.20)(0.23)
EPS (Diluted)(0.47)(0.34)(0.24)(0.20)(0.23)
Weighted Avg Shares27.84M28.36M28.8M29.32M32.62M
Weighted Avg Shares (Diluted)27.84M28.36M28.8M29.32M32.62M

Dyadic International, Inc.

NASDAQ:DYAI

Intrinsic Alpha fair value

Locked

Current Price

$1.47

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.